Literature DB >> 24157859

Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation.

Hiroki Kabata1, Kazuyo Moro, Koichi Fukunaga, Yusuke Suzuki, Jun Miyata, Katsunori Masaki, Tomoko Betsuyaku, Shigeo Koyasu, Koichiro Asano.   

Abstract

Type-2 innate immune responses that occur in airways and are accompanied by goblet-cell hyperplasia and mucus production are largely driven by interleukin-33 (IL-33) and natural helper (NH) cells, a member of group 2 innate lymphoid cells (ILC2s) and the major target of IL-33. Here we report that the corticosteroid resistance observed as a result of airway inflammation triggered by sensitization and exposure to allergen is induced via the IL-33/NH-cell axis. Thymic stromal lymphopoietin (TSLP) synthesized during airway inflammation plays a pivotal role in the induction of NH-cell corticosteroid resistance in vitro and in vivo, by controlling phosphorylation of STAT5 and expression of Bcl-xL in NH cells. Blockade of TSLP with a neutralizing antibody or blocking the TSLP/STAT5 signalling pathway with low molecular-weight STAT5 inhibitors such as pimozide restores corticosteroid sensitivity. Thus, the TSLP-STAT5 pathway could be a new therapeutic target in severe, corticosteroid-resistant asthma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24157859     DOI: 10.1038/ncomms3675

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  102 in total

1.  Dusp5 negatively regulates IL-33-mediated eosinophil survival and function.

Authors:  Derek A Holmes; Jung-Hua Yeh; Donghong Yan; Min Xu; Andrew C Chan
Journal:  EMBO J       Date:  2014-11-14       Impact factor: 11.598

2.  Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses.

Authors:  Kazuyo Moro; Hiroki Kabata; Masanobu Tanabe; Satoshi Koga; Natsuki Takeno; Miho Mochizuki; Koichi Fukunaga; Koichiro Asano; Tomoko Betsuyaku; Shigeo Koyasu
Journal:  Nat Immunol       Date:  2015-11-23       Impact factor: 25.606

Review 3.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 4.  Group 2 innate lymphoid cells in health and disease.

Authors:  Brian S Kim; David Artis
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-01-08       Impact factor: 10.005

5.  Potential Role of Mast Cells in Regulating Corticosteroid Insensitivity in Severe Asthma.

Authors:  Abdulrahman Alzahrani; Aamir Hussain; Fahad Alhadian; Jameel Hakeem; Sana Douaoui; Omar Tliba; Peter Bradding; Yassine Amrani
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Innate lymphoid cells: major players in inflammatory diseases.

Authors:  Mikaël Ebbo; Adeline Crinier; Frédéric Vély; Eric Vivier
Journal:  Nat Rev Immunol       Date:  2017-08-14       Impact factor: 53.106

Review 7.  Innate lymphoid cells-key immune integrators of overall body homeostasis.

Authors:  Fotios Karagiannis; Christoph Wilhelm
Journal:  Semin Immunopathol       Date:  2018-06-04       Impact factor: 9.623

8.  Neutralizing TNFα restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation.

Authors:  L Dejager; K Dendoncker; M Eggermont; J Souffriau; F Van Hauwermeiren; M Willart; E Van Wonterghem; T Naessens; M Ballegeer; S Vandevyver; H Hammad; B Lambrecht; K De Bosscher; J Grooten; C Libert
Journal:  Mucosal Immunol       Date:  2015-03-11       Impact factor: 7.313

9.  Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: The role of thymic stromal lymphopoietin.

Authors:  Sucai Liu; Mukesh Verma; Lidia Michalec; Weimin Liu; Anand Sripada; Donald Rollins; James Good; Yoko Ito; HongWei Chu; Magdalena M Gorska; Richard J Martin; Rafeul Alam
Journal:  J Allergy Clin Immunol       Date:  2017-04-20       Impact factor: 10.793

10.  Dexamethasone rapidly suppresses IL-33-stimulated mast cell function by blocking transcription factor activity.

Authors:  Anuya Paranjape; Oksana Chernushevich; Amina Abdul Qayum; Andrew J Spence; Marcela T Taruselli; Daniel Abebayehu; Brian O Barnstein; Jamie Josephine Avila McLeod; Bianca Baker; Gurjas S Bajaj; Alena P Chumanevich; Carole A Oskeritzian; John J Ryan
Journal:  J Leukoc Biol       Date:  2016-07-21       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.